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Background. Among the small proteoglycans, biglycan and
decorin have been proposed to be potent modulators of TGF-b-
mediated inflammatory kidney diseases. They were considered to
become induced during glomerulonephritis and to subsequently
inactivate the cytokine.
Methods. Decorin and biglycan as well as their endocytosis
receptor were investigated in normal rat renal cortex, in anti-
Thy-1 glomerulonephritis, in polycystic kidneys, in the remnant
kidney following 5/6-nephrectomy, and in kidneys from the Milan
normotensive strain by immunohistochemistry and in situ hybrid-
ization. Northern blots were used for the detection of mRNA
expression for decorin and biglycan in isolated glomeruli. Func-
tional aspects of the endocytosis of decorin and biglycan were
studied in cultured mesangial cells.
Results. In the normal adult rat kidney decorin was expressed
preferentially by Bowman’s capsule and by interstitial connective
tissue cells, but only in trace amounts by mesangial cells. In
contrast, biglycan was found in tubular epithelial cells, in associ-
ation with glomerular capillaries, podocytes and occasionally in
the mesangium. In the tubulointerstitium of diseased kidneys
(polycystic kidneys, 5/6-nephrectomy, kidneys from the Milan
normotensive strain) there was a general up-regulation of decorin
expression, while biglycan was localized only in distinct foci of
fibrotic lesions. Glomerulosclerosis (5/6-nephrectomy, Milan nor-
motensive strain) was associated with an increased staining for
both decorin and biglycan within glomeruli. However, even in the
anti-Thy-1 model of an acute mesangioproliferative glomerulone-
phritis where the greatest accumulation of decorin was found
there was only a slight enhancement of decorin mRNA in isolated
glomeruli. Decorin and biglycan become degraded upon receptor-
mediated endocytosis. Immunohistochemical investigations indi-
cated that the pattern of expression of the receptor protein
correlated well with the immunolocalization of both decorin and
biglycan. In vitro experiments with cultured mesangial cells pro-
vided direct evidence for the expression of the receptor and for
the cell’s capability to endocytose decorin as well as biglycan.
Conclusions. Decorin and biglycan are characterized by a
distinct expression pattern in the normal rat kidney, whereas the
presence of their endocytosis receptor protein correlates with the
expression of both proteoglycans. Decorin is almost completely
absent in the normal mesangium. Both proteoglycans become
up-regulated in various models of renal disease. The mesangial
accumulation of decorin in the anti-Thy-1 glomerulonephritis that
is observed in spite of the only slightly enhanced mRNA expres-
sion could result from decreased decorin turnover and/or in-
creased mesangial retention.
Decorin and biglycan are small chondroitin/dermatan
sulfate proteoglycans that are both widely distributed in
various extracellular matrices of mesenchymal origin. Bi-
glycan can also be found around some epithelial cells [1].
According to the structure of their core proteins they are
members of the family of proteoglycans with leucine-rich
repeat structures [reviewed in 2–4], and they carry either a
single glycosaminoglycan (GAG) chain in case of decorin
or up to two chains for biglycan. Decorin is well known to
interact via its core protein with several components of the
extracellular matrix, especially with various collagens, and
it may also have a role in growth control by influencing the
expression of p21 [5]. The most noted feature of decorin
knock out mice is skin fragility, most likely due to the
presence of thick and irregularly shaped collagen fibrils [6].
The precise biological role of biglycan is still under
discussion. It may associate with collagen fibrils, albeit with
lower affinity than decorin [7], and it may interact with
other matrix components, but its most common location is
on the cell surface or in the pericellular space [1]. Both
decorin and biglycan were shown to form complexes with
transforming growth factor-beta (TGF-b), which in certain
models results in the inactivation of the cytokine [8, 9]
whereas in others its activity was either not influenced or
even increased [10, 11]. In spite of these discrepancies it is
obvious that the concentrations of biglycan and decorin in
the tissues may be of great physiological importance.
The matrix content of both proteoglycans is logically the
result of the rates of biosynthesis and degradation.
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Whereas extracellular proteolytic degradation of both pro-
teoglycans has been described, complete degradation re-
quires the intralysosomal action of proteases, sulfatases and
glycosidases, and hence endocytosis of the two macromol-
ecules is a prerequisite for degradation. Fibroblasts and
other cells of mesenchymal origin are known to efficiently
internalize decorin by receptor-mediated endocytosis [12,
13]. Two proteins of 51 and 26 kD, respectively, which are
present at the plasma membrane and in endosomes, bind
decorin core protein with high affinity and are therefore
considered as receptor proteins [12, 14]. It seems that
biglycan core protein is recognized by the same receptor
proteins as decorin [13, 15]. The receptor proteins also
interact with membrane-associated heparan sulfate proteo-
glycans [14, 16]. The interaction of heparan sulfate with the
receptor proteins leads to an inhibition of decorin endocy-
tosis. Recently, the small proteoglycan endocytosis receptor
has been isolated, and direct evidence for the internaliza-
tion of the 51 kD receptor protein was provided [17].
Deficiencies of decorin and biglycan, both in the human
and in experimental animals, showed major abnormalities
in skin and bone [6, 18, 19]. The biological role of decorin
and biglycan in the kidney has mainly been inferred from
their TGF-b-binding and -neutralizing potency [8]. TGF-b
is considered to be a key mediator of fibrosis in both
experimental and human kidney diseases [20, 21]. On the
basis of the observation of an apparently TGF-b-mediated
dramatic up-regulation of biglycan and decorin in anti-Thy-
1-initiated mesangioproliferative glomerulonephritis, it had
been suggested that decorin is part of a negative feedback
system controlling cell growth and matrix turnover [22].
Indeed, it could be shown that the administration of
recombinant decorin [23] and the induction of decorin by
gene transfer [24] successfully suppressed the proteinuria
and the increased production of extracellular matrix com-
ponents in the anti-Thy-1 model. On the other hand,
immunocytochemical studies in normal rat kidney indi-
cated the presence of decorin only in the adventitia of
blood vessels. In experimental hydronephrosis decorin ex-
hibited additionally a periglomerular and peritubular local-
ization [25]. Such a localization would make it difficult to
understand the role of locally produced decorin in TGF-b
inactivation during glomerulonephritis.
Hence, the objectives of the present study were twofold:
(1) to demonstrate the localization of decorin and biglycan
in the normal rat kidney and in various models of renal
disease, using a set of different antibodies; and (2) to
provide evidence for the presence of the small proteoglycan
endocytosis receptor in the normal and diseased rat kidney
and to characterize this receptor in terms of the uptake of
decorin and biglycan by cultured rat mesangial cells.
METHODS
Animals and isolation of glomeruli
Adult male Sprague-Dawley rats weighing 225 to 250 g (2
months of age) were supplied by Charles-River (Sulzfeld,
Germany) and used for studies on the normal rat kidney.
Fibrotic kidneys were taken from one-year-old male rats of
the Milan normotensive strain (MNS) using age-matched
Milan hypertensive animals as a control [26] and from
20-month-old male, heterozygous Han:SPRD rats (cy/1)
suffering from polycystic kidney disease (PKD) [27]. Age-
matched unaffected littermates (1/1) served as controls.
Additionally, 5/6-nephrectomized, male Sprague-Dawley
rats 15 weeks after renal ablation (5/6-Nx) or sham opera-
tion [28] were used. The anti-Thy-1 glomerulonephritis was
induced by a single intravenous injection of mouse anti-rat
Thy-1.1 IgG dissolved in PBS, clone OX-7 (BioTrend,
Cologne, Germany), at a dose of 1 mg/kg body wt into
2-month-old, male Sprague-Dawley rats and kidneys were
harvested at day 7. Age-matched control animals were
receiving a single intravenous injection of PBS only. All
surgical procedures were performed under anesthesia with
hexobarbital (150 mg/kg body wt) and kidneys were per-
fused with cold 0.15 M NaCl before being removed. All
animal experiments were conducted in accordance with the
NIH Guide for the Care and Use of Laboratory Animals.
Glomeruli were isolated by differential sieving according
to the method of Spiro [29] and processed for Western
blotting or RNA isolation.
Cell culture
Rat mesangial cells were kindly provided by Dr. E.
Schulze-Lohoff, University of Erlangen, Germany, rat kid-
ney fibroblasts were from ATCC (cat. No. 6509; Rockville,
MD, USA) and rat skin fibroblasts were obtained from
explant cultures. All cells were maintained in modified
Eagle’s minimum essential medium supplemented with
10% fetal calf serum, non-essential amino acids and anti-
biotics [12].
Immunohistochemistry
The following primary antibodies against decorin were
applied in this study, their working dilution being given in
brackets: rabbit a-rat PDS II (1:500), which was raised
against rat decorin from rat fibroblast secretions [30];
rabbit LF 113 (1:300), being directed against a tetrade-
capeptide near the N-terminus of rat decorin core protein
[31]; and LN1 (1:50), a monoclonal antibody against human
decorin [32]. The specifity against decorin had been ascer-
tained before by preabsorption and competition experi-
ments. MAY-01 (1:500) is a newly developed chicken
antibody against a dodecapeptide located near the N-
terminus of the rat biglycan core protein (Ser67 - Gln78)
that did not react at a 1:100 dilution with purified rat or
human decorin; LF 106 (1:300) is a polyclonal rabbit
antibody against a murine biglycan peptide of 15 amino
acids (Arg12-Tyr26) [31]. The polyclonal rabbit antibody
against rat small proteoglycan endocytosis receptor (1:100)
as well as its affinity purified form (1:50 corresponding to
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an approximately 1000-fold dilution of the original anti-
serum used for affinity purification) has been described
recently [17].
For immunocytochemistry renal tissue was fixed with 4%
formaldehyde in 18 mM sodium phosphate, pH 7.4/0.15 M
NaCl (PBS). Paraffin sections (2 mm) were pretreated using
a set of different enzymes: 0.05% bacterial protease type
XXIV (EC 3.4.21.62; Sigma, Deisenhofen, Germany) for 2
to 15 minutes at 37°C, 0.05% protease type XIV from
Streptomyces griseus (EC 3.4.24.31; Dakopats, Hamburg,
Germany) for 2 to 10 minutes at room temperature, 7.5
mU/ml of chondroitin ABC lyase (EC 4.2.2.4; Sigma) for
two hours at 37°C prior to the administration of antibodies
raised against decorin or biglycan core protein [1] and with
25 mU/ml of heparitinase (EC 4.2.2.8; Seikagaku Kogyo,
Tokyo, Japan) for two hours at 37°C in order to digest the
heparan sulfate prior to incubation with the antibody
against the small proteoglycan endocytosis receptor. The
sections were subsequently blocked overnight at 4°C using
10% normal goat serum (Dakopats) and 5% bovine serum
albumin (BSA; Sigma) in 0.05 M Tris-buffered saline (TBS)
and incubated with the primary antibody in a moist cham-
ber for one hour at ambient temperature. After washing,
the sections were incubated with secondary antibodies
(Dakopats): mouse anti-rabbit immunoglobulins (1:125 in
TBS containing 1% BSA for 30 min at room temperature)
and subsequently with rabbit anti-mouse (1:30 in TBS
containing 1% BSA and 12.5% normal rat serum) for 30
minutes at room temperature. In the case of the monoclo-
nal antibody LN1 the first bridging antibody was omitted.
For MAY-01 rabbit anti-chicken immunoglobulins (Sigma;
1:100 in TBS containing 1% BSA) were used as the first
bridging antibodies. To complete the sandwich technique a
soluble complex of alkaline phosphatase anti-alkaline phos-
phatase (APAAP; Dakopats) was added [33]. The last two
steps were repeated to enhance the intensity of the reac-
tion. The enzyme label was visualized with naphthol
AS-MX-phosphatase (Sigma) and fast red dye (Sigma) in
the presence of levamisole (Sigma) in order to block
endogenous alkaline phosphatase. The slides were counter-
stained with Mayer’s hemalaun (Sigma) and covered with
glycerol-gelatin. The specifity of immunolabeling was
tested by omitting the primary antibody and by using
non-immune serum or “unspecific” IgG instead. In the case
of the endocytosis receptor, the specificity was tested
additionally by using an antiserum in which the receptor-
specific antibodies had been removed by adsorption to
immobilized receptor protein.
Northern blot analysis
Northern blot analysis was performed as described pre-
viously [34]. Briefly, RNA was extracted from glomeruli or
mesangial cells using TRI-zol (Life Technologies, Eggen-
stein, Germany). All probes were radiolabeled with
[32P]dCTP (Amersham-Buchler, Braunschweig, Germany)
using the DECAprime DNA labeling kit (Ambion, Austin,
TX, USA). Hybridization was carried out overnight at
42°C. The filters were exposed to Kodak X-OMAT AR film
at 280°C for one day.
The cDNA probes for rat biglycan and decorin were
obtained by RT-PCR. Total rat kidney RNA (1 mg) was
reverse-transcribed with Super Script II reverse transcrip-
tase (Life Technologies) and random hexanucleotides for
cDNA priming. Double-stranded cDNAs were generated
by amplification of the reverse-transcribed RNA by using
primers that contained additionally appropriate sequences
with restriction sites for EcoRI and NotI, respectively. For
decorin the forward primer was 59-TGC TGG AAT TCC
CCG GAT TAA AAG GTG GTG A-39, and the reverse
and complement primer was 59-CTC GAG CGG CCG
CTG AGG CTG TTT GGG AGT TAC-39, thus yielding a
rat decorin cDNA encompassing bp 179-1238 [35]. For rat
biglycan the respective primers were 59-TGC TGG AAT
TCC CTC CCC AGG AAC ATT GAC-39 and 59-CTC
GAG CGG CCG CGC CAT GGT GGC TAC CAC TG-39,
which allowed the generation of a biglycan cDNA between
bp 123 and 1230 [36]. After restriction endonuclease treat-
ment the PCR products were cloned into pcDNA3.1 (In-
vitrogen, Carlsbad, CA, USA) and verified by sequencing.
In situ hybridization
A decorin cDNA probe comprised nucleotides 89 to 984
of the rat decorin cDNA [35].
A biglycan cDNA probe was obtained from a full-length
human biglycan cDNA [37] being cloned into the pBlue-
script plasmid (Stratagene, La Jolla, CA, USA). After
digestion with EcoRI/HincII a 831 bp fragment was cloned
into pGEM-4Z (Promega, Madison, WI, USA) and subse-
quently subjected to restriction with StuI/HincII, thus yield-
ing a 278 bp biglycan insert (position 240-518) with a
homology to rat biglycan of 88.4%. Sense and antisense
riboprobes were transcribed in vitro from the linearized
plasmids using digoxygenin-labeled UTP and the SP6/T7-
RNA polymerase kit (DIG RNA Labeling Kit SP6/T7;
Boehringer Mannheim, Germany).
Tissue sections were deparaffinized with xylene and
rehydrated in a descending ethanol series. Cell membranes
were permeabilized by digestion for three to six minutes at
37°C with 3 mg/ml proteinase K (Boehringer) in 20 mM
Tris/HCl, pH 8.0, containing 2 mM CaCl2. After refixation
with 4% paraformaldehyde in PBS for 20 minutes on ice
and acetylation with 0.1 M triethanolamine/0.25% acetic
anhydride for 10 minutes the specimens were incubated
with prehybridization buffer (50% deionized formamide,
1 3 Denhardt’s solution, 0.5 mg/ml denatured salmon
sperm DNA, 0.25 mg/ml yeast tRNA, 10% dextran sulfate
and 1% 1 M DTT in 2 3 SSC) in a humid chamber at 49°C
for two hours. The hybridization solution contained the
appropriate riboprobe at a final concentration of about 7.5
ng/ml in prehybridization buffer. Hybridization was for 16
Schaefer et al: Small proteoglycans and their endocytosis receptor 1531
hours at 49°C. Thereafter, the specimens were washed
twice for 20 minutes with 50% formamide and 1% 2-mer-
captoethanol in 2 3 SSC, 20 minutes in 2 3 SSC, and 10
minutes in 0.1 3 SSC at 50°C. Immunological detection of
the probe/mRNA hybrids was performed as described [38]
with some modifications. The sections were blocked with
2% normal sheep serum and 0.05% Triton X-100 in 2 3
SSC for two hours, washed twice for five minutes with 50
mM Tris/HCl, pH 7.5, containing 225 mM NaCl (buffer 1)
before the antibody solution (alkaline phosphatase-conju-
gated Fab fragments of anti-digoxygenin antibodies
(Boehringer Mannheim) at a dilution of 1:1000, 1% normal
sheep serum, 0.3% Triton X-100 in buffer 1) was applied in
a humid chamber for two hours at 37°C. To remove the
unbound antibody conjugate, the slides were washed twice
with buffer 1. Thereafter, they were equilibrated for 10
minutes with 100 mM Tris/HCl, pH 9.5, containing 100 mM
NaCl and 50 mM MgCl2 (buffer 2). Endogenous alkaline
phosphatase was blocked by 5 mM levamisole, and the
digoxygenin/anti-digoxygenin conjugates were visualized
upon reaction with 0.15 mg/ml 5-bromo-4-chloro-3-indolyl
phosphate/0.3 mg/ml nitroblue tetrazolium (FAST BCIP/
NBT; Sigma) in 100 mM Tris/HCl, pH 9.5/5 mM MgCl2 for
16 hours at 4°C. The slides were then dehydrated and
observed without counterstain.
Other methods
Endocytosis experiments were performed exactly as de-
scribed before [12]. [35S]sulfate-labeled decorin was either
obtained from the media of human skin fibroblasts or from
the media of 293 cells stably transfected with a human
decorin cDNA [39]. [35S]sulfate-labeled biglycan was anal-
ogously obtained from 293 cells transfected with a human
biglycan cDNA. Proteoglycan purification was achieved by
ion exchange chromatography [12] followed by chromatog-
raphy on a 1 ml phenyl-Sepharose column prepared in a
Pasteur pipet and equilibrated with 2 M (NH4)2SO4 in 10
mM potassium phosphate, pH 6.8. The column was washed
with 0.2 M (NH4)2SO4 in potassium phosphate buffer, and
small proteoglycans were subsequently eluted with water.
Since endocytosis of decorin and biglycan is followed by
intralysosomal degradation, and the resulting products are
in part released into the culture medium, endocytosis is
represented by the sum of the intracellular radioactivity
and the ethanol-soluble radioactivity in the culture me-
dium. For comparison, endocytosis is usually expressed as
clearence rate, giving the volume of incubation medium (in
microliters) cleared from the labeled material per hour and
per milligram cell protein. Western blotting using poly-
clonal antibodies against the rat decorin endocytosis recep-
tor was performed as described earlier [13].
RESULTS
Immunolocalization and mRNA expression of decorin
and biglycan in normal rat kidney
In the adult rat kidney decorin was immunolocalized in
the interstitial connective tissue, with focal concentrations
around tubular structures, in the adventitia of blood vessels
and in the perivascular space, and in the Bowman’s capsule
of glomeruli. Only trace amounts of decorin could be
detected in the mesangium after employing two successive
rounds of the APAAP technique (Fig. 1). These staining
patterns were observed with a polyclonal antibody against
the full-length core protein prepared from rat fibroblast
cultures (a-PDS) (Fig. 1), a polyclonal antiserum against a
decorin-derived peptide linked with horseshoe crab hemo-
cyanin (LF113) and a monoclonal antibody against human
decorin that cross-reacts with the proteoglycan from rat
tissue (LN1). With all three antibodies, however, it was
necessary to pretreat the tissue sections with one of the
proteases or with chondroitin ABC lyase, but the different
protocols described for proteolytic pretreatment yielded
similar results.
In agreement with the histochemical findings, in situ
hybridization for decorin gave a distinct signal in Bowman’s
capsule cells and a stronger one in the adventitia and
around tubules, that is, presumably in mesenchymal cells
located between tubuli. In the mesangium the signal was
confined to few mesangial cells (Fig. 1).
Collecting ducts, distal tubules as well as vessel walls
stained strongly positive for biglycan. It could also be
detected within glomeruli where it was mainly associated
with capillaries, but was visible within the mesangium and
around podocytes, too (antibody MAY-01; Fig. 1). An
identical staining pattern for biglycan in the normal rat
kidney could be observed with the LF 106 antiserum (data
not shown). In situ hybridization studies supported the
cytochemical results (Fig. 1).
As expected from the relatively strong signals seen in
Bowman’s capsule cells upon in situ hybridization, North-
ern blot analyses of total RNA from isolated rat glomeruli
demonstrated the presence of both decorin and biglycan
mRNA (Fig. 2A).
Presence of the small proteoglycan endocytosis receptor
in normal rat renal cortex
The quantity of decorin and biglycan in the tissue
represents the balance between biosynthesis and secretion
on the one hand and endocytosis and degradation on the
other hand. Since we had recently been able to raise a
monospecific antiserum against the rat decorin endocytosis
receptor, which is probably also responsible for the uptake
of biglycan, we searched for the presence of the receptor in
the kidney. As it is shown in Figure 3, the endocytosis
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Fig. 1. Decorin and biglycan immunohistochemistry (IHC-APAAP, decorin in glomerulus 31000 and decorin in tubulointerstitium 3200 using a-PDS
1:500 after pretreatment with 0.05% protease type XXIV for 10 min at 37°C; biglycan in glomerulus 3600, biglycan in tubulointerstitium 3400 using
MAY-01 1:500 after pretreatment with 7.5 mU/ml of chondroitin ABC lyase for 2 hours at 37°C) and in situ hybridization (ISH, decorin in glomerulus:
left panel 3600, right panel 31200 and in tubulointerstitium 31200; biglycan in glomerulus 31000 and in tubulointerstitium 3600), using
digoxygenin-labeled anti-sense riboprobes, in the glomerulus and tubulointerstitium of normal rat kidney. Negative controls for IHC were performed
using non-immune rabbit IgG (for decorin) and non-immune chicken IgG (for biglycan) as substitution for the primary antiserum (3100). As negative
controls for ISH digoxygenin-labeled sense riboprobes for decorin and biglycan were used (3100).
receptor exhibited a similar distribution as both decorin
and biglycan.
The observed staining, however, depended on the type of
digestion used prior to the administration of the first
antibodies. “Mild” digestion using protease type XIV for 2
to 10 minutes at room temperature or protease type XXIV
for up to eight minutes at 37°C revealed traces of staining
in the glomerulus and strong positivity in distal tubules and
collecting ducts (Fig. 3A). Digestion with heparitinase
showed additional staining in peritubular mesenchymal
cells (data not shown). “Strong” digestion with protease
XXIV over 10 minutes at 37°C almost completely abolished
this pattern of staining and revealed the localization of the
receptor in Bowman’s capsule and in mesenchymal cells
around tubules (Fig. 3B).
Western blots using polyclonal antibodies to the small
proteoglycan endocytosis receptor detected the presence of
a 51 kD protein in the homogenate of isolated glomeruli
(Fig. 2B, lane 1) in agreement with the purified endocytosis
receptor protein from rat brain (Fig. 2B, lane 2). An
additional protein band of 46 kD could be detected in
isolated glomeruli, which corresponds well with earlier
findings [17] and most likely represents a degradation
product of the receptor because of its cross-reactivity with
affinity-purified antibodies.
Immunolocalization of decorin, biglycan and their
endocytosis receptor in fibrotic rat kidneys
In light of the potential role of small proteoglycans in the
development of renal fibrosis, we studied the expression of
decorin, biglycan and of their endocytosis receptor in
different models of tubulointerstitial fibrosis and glomeru-
losclerosis. The Han:SPRD rat represents a model of
polycystic kidney disease with an accumulation of a collag-
enous matrix around atrophic and dilated tubules without
any glomerulosclerosis. In the remnant kidney after renal
ablation (5/6-Nx) glomeruli become hypertrophic and scle-
rotic, and considerable quantities of extracellular matrix
accumulate in the tubulointerstitium. In the Milan normo-
tensive strain (MNS) focal glomerulosclerosis and intersti-
tial fibrosis can be observed. In all these models of exper-
imental kidney disease immunohistochemistry revealed a
remarkable over-expression of decorin in the tubulointer-
stitium compared to the normal rat kidney. In 5/6-Nx and
Fig. 2. (A) Northern blot analysis of decorin
(DCN 1.8 kb) and biglycan (BGN 2.6 kb) in
glomeruli from control animals and from the
anti-Thy-1 glomerulonephritis (anti-Thy-1 GN).
28S and 18S rRNA correspond to 4.8 and 1.9
kb, respectively. Densitometric analysis was
normalized to GAPDH expression (lower
panel). (B) Western blot analysis of the small
proteoglycan endocytosis receptor in glomeruli
from normal kidneys showing 51 kD and 46 kD
protein bands (lane 1) and purified receptor
protein (51 kD) from rat brain (lane 2).
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Fig. 3. Immunostaining of small proteoglycan endocytosis receptor in normal rat kidney cortex. (A) After pretreatment with protease type XIV for
six minutes at room temperature demonstrating traces of staining in the glomerulus and strong positivity in distal tubules and collecting ducts (APAAP,
glomerulus 31000, tubulointerstitium 3400). (B) After pretreatment with protease type XXIV for 12 minutes at 37°C showing weak positivity in
Bowman’s capsule and in peritubular mesenchymal cells (APAAP, glomerulus 3600, tubulointerstitium 31000). Negative controls were performed
using an antiserum from which the receptor-specific antibodies had been removed by adsorption to immobilized receptor protein (3100).
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Fig. 5. Immunohistochemistry of small
proteoglycan endocytosis receptor in polycystic
kidney disease after pretreatment with protease
type XXIV for 12 minutes at 37°C (PKD,
3200), 5/6-nephrectomy (5/6-Nx, 3600) and
Milan normotensive strain (MNS, 3320) after
pretreatment with protease type XIV for six
minutes at room temperature (APAAP).
MNS an increased immunostaining for decorin was also
seen within afflicted glomeruli (Fig. 4).
In all of these models the quantity of immunoreactive
biglycan appeared to be slightly increased in the tubuloin-
terstitial space, while the staining in distal tubules and
collecting ducts was comparable with the normal kidney.
Biglycan staining was more pronounced in polycystic kid-
ney disease with additional labeling of atrophic proximal
Fig. 4. Immunohistochemistry of decorin (a-PDS, 1:500 after pretreatment with 0.05% of protease type XXIV for 10 min at 37°C) and biglycan
(MAY-01, 1:500 after pretreatment with 7.5 mU/ml of chondroitin ABC lyase for 2 hr at 37°C) in polycystic kidney disease (PKD, 3200),
5/6-nephrectomy (5/6-Nx,decorin 3600, biglycan 3400) and Milan normotensive strain (MNS, decorin 3400, biglycan 3600) (APAAP).
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tubules. In the model of experimental glomerulosclerosis
(5/6-Nx, MNS) there was clear overexpression of bigly-
can in the mesangium (Fig. 4). Immunolocalization of
either proteoglycan in the respective age-matched con-
trol kidneys was identical with the normal kidney (data
not shown).
The small proteoglycan endocytosis receptor was also
stained more intensely in fibrotic kidneys as compared to
the normal parenchyma, and it co-localized quite well with
areas staining for both decorin and biglycan (Fig. 5). Again,
“mild” and “strong” digestion gave different staining pat-
terns. With “mild” digestion relatively strong staining for
the receptor was visible in distal tubules and collecting
ducts (data not shown) and within the mesangium of
sclerotic glomeruli (Fig. 5). “Strong” digestion resulted in
marked immunolabeling of peritubular mesenchymal cells
in fibrotic lesions, particularly in the model of polycystic
kidney disease (Fig. 5).
Expression and immunolocalization of decorin, biglycan
and their endocytosis receptor in acute
mesangioproliferative glomerulonephritis
A single injection of the monoclonal anti-thymocyte
antibody (anti-Thy-1.1) in the rat leads to mesangiolysis
followed by mesangial proliferation and accumulation of
extracellular matrix. Strong focal immunostaining of both
decorin and biglycan could be observed in the mesangium
of injured glomeruli (Fig. 6). Parallel to the focal accumu-
lation of decorin and biglycan, the endocytosis receptor was
more strongly stained in afflicted glomeruli, co-localizing
with areas of matrix accumulation (Fig. 6). Isolated glomer-
uli from anti-Thy-1 kidneys, harvested at day 7, revealed
only a slight enhancement of decorin mRNA expression
(1.5 6 0.2 times, N 5 3) compared to glomeruli from
control kidneys, while biglycan mRNA expression was
increased 6.2 6 0.4 times (N 5 3; Fig. 2A). In situ
hybridization studies corroborated the finding of an in-
creased biglycan expression, while the signal for decorin
was at the limit of detection (Fig. 6).
Endocytosis of decorin and biglycan by cultured
mesangial cells
To gain further insight into the dynamics of small
proteoglycan metabolism rat mesangial cells were cultured
in vitro, and their capability to endocytose small proteogly-
cans was investigated. Although these cells may dediffer-
entiate in vitro, tissue culture systems nevertheless may
indicate metabolic capabilities of defined cell types. In a
first set of experiments decorin uptake by rat skin fibro-
blasts, renal fibroblasts and mesangial cells was compared.
[35S]sulfate-labeled decorin was prepared under non-dena-
turing conditions from the conditioned media of human
skin fibroblasts and added at a concentration of 40,000
cpm/ml culture medium to the three different rat cell types.
After four hours of incubation uptake was measured and
expressed as clearance rate (volume of culture medium
cleared from radioactive decorin per hour and mg cell
protein). The clearance rates were 37 ml/hr and mg for skin
fibroblasts, 34 ml/hr and mg for renal fibroblasts, and 27
ml/hr and mg for mesangial cells. Since fluid-phase uptake
accounts for less than 0.1 ml/hr and mg, these data indicate
the capacity of mesangial cells for receptor-mediated up-
take of decorin.
For a comparative study of the endocytosis of decorin
and biglycan the respective [35S]sulfate-labeled proteogly-
cans were obtained from the media of 293 cells that had
been stably transfected with human biglycan and decorin
cDNA, respectively. Non-transfected 293 cells neither syn-
thesize decorin nor biglycan, and the two proteoglycans
could therefore be separately obtained by a purification
scheme avoiding denaturing agents. When cells were incu-
bated in the presence of labeled proteoglycan (100,000 to
200,000 cpm/ml) for three hours, clearance rates of 16.2 6
3.2 ml/hr and mg (N 5 9) and 49.9 6 8.7 ml/hr and mg (N 5
6) were obtained in several independent experiments for
the uptake of decorin and biglycan, respectively. A typical
experiment for the dose-dependency of uptake is shown in
Figure 7. The data show that a greater proportion of
radioactive biglycan than of radioactive decorin could be
endocytosed. This finding, however, should be judged in the
context that, in contrast to decorin, the majority of biglycan
molecules is linked with two glycosaminoglycan chains and
therefore may have more 35S-label per molecule. It is not
yet understood why there was a greater difference between
mesangial cells and fibroblasts in the endocytosis of bigly-
can than in the uptake of decorin. The data available so far
are in favor of assuming a single receptor for both proteo-
glycans.
DISCUSSION
Small proteoglycans, especially decorin, are intensely
studied components of the extracellular matrix of the
kidney because of their suggested capability to control
mesangial proliferation and matrix accumulation. How-
ever, somewhat conflicting data on their presence in the
kidney have been reported. By using a monoclonal anti-
body against decorin core protein Diamond et al had shown
only periadventitial immunolabeling of decorin and no
glomerular reactivity in the normal rat kidney [25]. How-
ever, it could not be excluded that the reactive epitope was
masked at other locations, for example, by the glycosami-
noglycan chain [40]. We have therefore employed, using a
very sensitive staining technique, two polyclonal antisera in
addition to the monoclonal antibody used before [25]. The
three reagents gave identical staining patterns. However,
pretreatment with either proteases or chondroitin ABC
lyase was necessary. From the results obtained, it seems
safe to conclude that decorin is present in the normal
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glomerulus preferentially in Bowman’s capsule and not in
the mesangium. The demonstration of decorin in cultured
glomeruli [22] and of decorin mRNA in freshly isolated
glomeruli [41, this study] can, therefore, not be attributed
solely to the presence of mesangial cells.
The presence of biglycan in the glomeruli was to be
expected since biglycan seems to be constitutively ex-
pressed by endothelial cells [42]. It is also present in the
mesangium and podocytes, but the focal accumulation in
some glomeruli remains unexplained primarily because of
Fig. 6. Immunohistochemistry (IHC-APAAP) of decorin (a-PDS), bigly-
can (MAY-01, 3200) and their endocytosis receptor (3120) as well as in
situ hybridization (ISH) of decorin (3600) and biglycan (3320) in the
renal cortex from animals with acute mesangioproliferative glomerulone-
phritis (anti-Thy-1 GN).
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the insufficient knowledge of potential biglycan-binding
proteins. The association of biglycan with the epithelia of
collecting ducts had been mentioned before [1] whereas the
presence in distal tubules is described here for the first
time, to our knowledge.
As the quantity of the small proteoglycans results from
the net rates of biosynthesis and degradation that occurs
after receptor-mediated endocytosis, we have also investi-
gated the immunocytochemical localization of the endocy-
tosis receptor. From competition and direct binding exper-
iments it is likely that the 51 kD decorin receptor protein is
also involved in the uptake of biglycan [13, 15]. The present
study, using affinity-purified antibodies and the crude anti-
serum with similar results, clearly demonstrates the pres-
ence of the receptor, albeit in small amounts, in mesangial
cells as well as in cells of the Bowman’s capsule. In
addition, immunostaining was also seen in distal tubules,
collecting ducts and interstitial mesenchymal cells. This
pattern of expression of the receptor protein correlates well
with the immunolocalization of both decorin and biglycan.
It is also in agreement with our in vitro results showing that
both mesangial cells and renal fibroblasts in culture are
capable of receptor-mediated uptake of decorin and bigly-
can. It should be kept in mind, however, that reactive
epitopes of the receptor protein may be masked to a
different degree depending on the localization within the
tissue. From a functional point of view it is also noteworthy
that the extent of small proteoglycan endocytosis is not only
a function of their concentration and of the receptor
expression but additionally depends on the quantity and
domain structure of cell-associated heparan sulfate [16].
Studies are underway to address these questions in isolated
glomeruli and in cultured mesangial cells.
In the models of experimental renal disease studied here,
an increased immunostaining for both decorin and biglycan
within glomerular lesions was observed (5/6-Nx, MNS). A
more intense staining for decorin was seen throughout the
tubulointerstitium whereas biglycan accumulated in distinct
foci (5/6-Nx, MNS and PKD). For decorin, similar findings
were obtained in kidney biopsies from patients with renal
diseases of various etiologies [43, 44]. An increased decorin
staining was found in the tubulointerstitial space, and the
proteoglycan turned out to be a good predictor of the
severity of interstital fibrosis and the progression of renal
failure [43].
In the present investigation the strongest overexpression
of decorin and biglycan within the mesangium was detected
in acute mesangioproliferative glomerulonephritis (anti-
Thy-1 model); however, this finding was limited to certain
glomeruli and the average decorin mRNA level of isolated
glomeruli rose only by a factor of 1.5. In the anti-Thy-1
model of glomerulonephritis the role of TGF-b for the
development of glomerulosclerosis and the beneficial effect
of decorin administration have been clearly demonstrated
[23]. In other models of glomerulosclerosis, however, the
increase of decorin appeared to be greater in the tubuloint-
erstitium than in the mesangium. This increase was seen in
spite of the apparent up-regulation of the endocytosis
receptor. With regard to the potential regulatory role of
decorin during development of TGF-b-mediated renal
fibrosis our results, are in agreement with the assumption
that the up-regulation of decorin allows the formation of a
ternary complex of matrix-bound decorin and TGF-b to a
greater extent, thereby withdrawing the cytokine from its
cell membrane receptors. Considering the rather modest
increase of decorin, at least in the glomeruli, it also seems
possible that low levels of soluble decorin bind to low levels
of soluble TGF-b, and that these complexes are not
retained at the site of formation but are removed by
diffusion and blood flow or, alternatively, by endocytosis.
Thus, the levels of decorin in tissue sections do not
necessarily reflect the effects of the proteoglycan on the
bioactivity of TGF-b, and it may be worthwhile to follow
blood levels of decorin during the development of tissue
fibrosis.
Fig. 7. Endocytosis of decorin (A) and biglycan (B) by human skin
fibroblasts (F) and rat mesangial cells (E). Cells were incubated for three
hours with the indicated amounts of [35S]sulfate-labeled recombinant
human proteoglycan expressed in 293 cells.
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